CyPath Lung sales triple year-over-year at bioAffinity
bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth of over 200% to a new record driven by increased physician adoption and repeat utilization. The acceleration in test volume underscores a strong commercial trajectory for the company's non-invasive lung cancer diagnostics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day